1-6 of 6
J. Porter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Alternative Reduced Intensity Conditioning for Allogeneic Blood and Marrow Transplantation Using Pentostatin, Cyclophosphamide, and Total-Body Irradiation with Post-Transplant Cyclophosphamide

Timothy J. Porter, Haval Norman, Javier Bolanos-Meade, Leo Luznik, Jamie E. Ziggas, Amy E. DeZern, Ephraim J. Fuchs, Richard J. Jones
Journal: Blood
Blood (2022) 140 (Supplement 1): 7601–7602.
https://doi.org/10.1182/blood-2022-166641
Published: 2022
Journal Articles

Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy

Hani Jrade, PhD, Harinad B Maganti, PhD, Christopher Cafariello, Christopher J Porter, Julien Yockell-Lelièvre, PhD, Hannah L Battaion, Safwat T Khan, Joel P Howard, Theodore J Perkins, PhD, Mitchell Sabloff, MD, Caryn Y Ito, PhD, William L. Stanford, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5232.
https://doi.org/10.1182/blood-2018-99-117281
Published: 2018
Journal Articles

Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.

M.D. Cappellini, P. Giardina, J. Porter, T. Coates, M.G. Della Porta, J. Siegel, E. Glimm, J. Ford
Journal: Blood
Blood (2006) 108 (11): 1768.
https://doi.org/10.1182/blood.V108.11.1768.1768
Published: 2006
Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2334.
https://doi.org/10.1182/blood.V106.11.2334.2334
Published: 2005
Journal Articles

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

J. Porter, C. Borgna-Pignatti, M. Baccarani, A. Saviano, S. Abish, R. Malizia, H. Nick, H. Opitz, B. Rabault, I. Gathmann, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2690.
https://doi.org/10.1182/blood.V106.11.2690.2690
Published: 2005
Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 313.
https://doi.org/10.1182/blood.V106.11.313.313
Published: 2005